Roche Q3 Revenue Exceeds Expectations Despite Slight Miss in Pharmaceutical Sales
Roche reported third-quarter revenue of CHF 16.13 billion ($19.61 billion), representing a 7% year-over-year increase. This top-line figure surpassed market consensus estimates, which had projected CHF 15.75 billion ($19.15 billion). Despite the overall revenue beat, the company's pharmaceutical division saw sales of $14.85 billion, falling slightly short of analyst expectations. The results present a mixed performance picture as strong total revenue growth was tempered by the minor miss in core pharma segment performance.
Tickers: $RHHBY